A single-center randomized controlled trial of local methylcobalamin injection for subacute herpetic neuralgia

Pain Medicine (United States)

Volumn 14, Issue 6, 2013, Pages 884-894

  Xu, Gang ^a   Lv, Zhong Wei ^a   Feng, Yan ^a   Tang, Wei Zhen ^a  

^a Xiao)   (China)

Author keywords

Cobalamin; Randomized clinical trial; Subacute herpetic neuralgia; Subcutaneous injection

Indexed keywords

ACICLOVIR; AMITRIPTYLINE; GABAPENTIN; LIDOCAINE; MECOBALAMIN; OXYCODONE; PREGABALIN; TRAMADOL; VALACICLOVIR;

ADULT; ALLODYNIA; ANALGESIA; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INJECTION; INJECTION SITE CONTUSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; ONSET AGE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PARESTHESIA; POSTHERPETIC NEURALGIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN IRRITATION; TREATMENT DURATION; TREATMENT RESPONSE; WEAKNESS;

EID: 84879501348     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12081     Document Type: Article

References (55)

1. Quinlivan M, Breuer J. Molecular studies of varicella zoster virus. Rev Med Virol 2006;16:225-50.
2. Gilden D, Mahalingam R, Nagel MA, et al. Review: The neurobiology of varicella zoster virus infection. Neuropathol Appl Neurobiol 2011;37:441-63.
3. Esiri MM, Tomlinson AH. Herpes zoster. Demonstration of virus in trigeminal nerve and ganglion by immunofluorescence and electron microscopy. J Neurol Sci 1972;15:35-48.
4. Haanpaa M, Laippala P, Nurmikko T. Allodynia and pinprick hypesthesia in acute herpes zoster, and the development of postherpetic neuralgia. J Pain Symptom Manage 2000;20:50-8.
5. Niv D, Maltsman-Tseikhin A. Postherpetic neuralgia: The never-ending challenge. Pain Pract 2005;5:327- 40.
6. Arani RB, Soong SJ, Weiss HL, et al. Phase specific analysis of herpes zoster associated pain data: A new statistical approach. Stat Med 2001;20:2429-39.
7. Desmond RA, Weiss HL, Arani RB, et al. Clinical applications for change-point analysis of herpes zoster pain. J Pain Symptom Manage 2002;23:510-16.
8. Helgason S, Petursson G, Gudmundsson S, et al. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: Prospective study with long term follow up. BMJ 2000;321:794-6.
9. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007;44:S1-26.
10. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.
11. Zaichick SV, Bohannon KP, Smith GA. Alphaherpesviruses and the cytoskeleton in neuronal infections. Viruses 2011;3:941-81.
12. Oaklander AL. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Pain 2001;92:139-45.
13. Petersen KL, Rice FL, Farhadi M, et al. Natural history of cutaneous innervation following herpes zoster. Pain 2010;150:75-82.
14. Whitley RJ, Volpi A, McKendrick M, et al. Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol 2010;48:S20-8.
15. Dror DK, Allen LH. Effect of vitamin B12 deficiency on neurodevelopment in infants: Current knowledge and possible mechanisms. Nutr Rev 2008;66:250-5.
16. Okada K, Tanaka H, Temporin K, et al. Methylcobalamin increases Erk1/2 and Akt activities through the methylation cycle and promotes nerve regeneration in a rat sciatic nerve injury model. Exp Neurol 2010; 222:191-203.
17. Inada M. Tissue distribution of vitamin B12 and its dynamics in nervous tissues. Nihon Rinsho 1999; 57:2307-12.
18. Solomon LR. Disorders of cobalamin (vitamin B12) metabolism: Emerging concepts in pathophysiology, diagnosis and treatment. Blood Rev 2007;21:113-30.
19. Duyvendak M, Veldhuis GJ. Oral better than parenteral supplementation of vitamin B12. Ned Tijdschr Geneeskd 2009;153:B485.
20. Butler CC, Vidal-Alaball J, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: A systematic review of randomized controlled trials. Fam Pract 2006;23:279-85.
21. Yaqub BA, Siddique A, Sulimani R. Effects of methylcobalamin on diabetic neuropathy. Clin Neurol Neurosurg 1992;94:105-11.
22. Ide H, Fujiya S, Asanuma Y, et al. Clinical usefulness of intrathecal injection of methylcobalamin in patients with diabetic neuropathy. Clin Ther 1987;9:183-92.
23. Solomon LR. Oral pharmacologic doses of cobalamin may not be as effective as parenteral cobalamin therapy in reversing hyperhomocystinemia and methylmalonic acidemia in apparently normal subjects. Clin Lab Haematol 2006;28:275 .
24. Dworkin RH, Gnann JW, Jr, Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008;9: S37-44.
25. Watson CPN, Gershon AA. Herpes Zoster and Postherpetic Neuralgia, 2nd rev. and enlarged edition. New York: Elsevier; 2001.
26. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19.
27. Semionov V, Shvartzman P. Post herpetic itching-A treatment dilemma. Clin J Pain 2008;24:366-8.
28. Oaklander AL. Neuropathic itch. Semin Cutan Med urg 2011;30:87-92.
29. Farrar JT, Young JP, Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58.
30. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21.
31. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the Brief Pain Inventory. J Pain 2004; 5:344-56.
32. EuroQol Group. EuroQol-A new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
33. Wood MJ, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: A meta-analysis of placebo-controlled trials. Clin Infect Dis 1996;22:341-7.
34. Kaipainen WJ. Vitamin B12 in zoster neuralgia. Duodecim 1994;110:1789-91.
35. Rabinstein S, Bumaguin De Rabinstein S. Action of vitamin B-1 and B-12 in massive doses in posterpes zoster neuralgia. Sem Med 1962;121:158-61
36. Helle J, Ohela K. Treatment of herpes zoster neuralgia with massive doses of vitamin B12. Ann Med Exp Biol Fenn 1955;33:116-21.
37. Heaton JM. Vitamin B12 and herpes zoster ophthalmicus. Br J Ophthalmol 1959;43:438-9.
38. Healton EB, Savage DG, Brust JC, et al. Neurologic spects of cobalamin deficiency. Medicine 1991; 0:229-45.
39. Karnaze DS, Carmel R. Neurologic and evoked potential abnormalities in subtle cobalamin deficiency states, including deficiency without anemia and with normal absorption of free cobalamin. Arch Neurol 1990;47:1008-12.
40. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988;318:1720-8.
41. Zhang YF, Ning G. Mecobalamin. Expert Opin Investig Drugs 2008;17:953-64.
42. Kong X, Sun X, Zhang J. The protective role of Mecobalamin following optic nerve crush in adult rats. Yan Ke Xue Bao 2004;20:171-7.
43. Talaei A, Siavash M, Majidi H, Chehrei A. Vitamin B12 may be more effective than nortriptyline in improving painful diabetic neuropathy. Int J Food Sci Nutr 2009;60(suppl 5):71-6.
44. Sun Y, Lai MS, Lu CJ. Effectiveness of vitamin B12 on diabetic neuropathy: Systematic review of clinical controlled trials. Acta Neurol Taiwan 2005;14:48-54.
45. Quadros EV. Advances in the understanding of cobalamin assimilation and metabolism. Br J Haematol 2010;148:195-204.
46. Petrus AK, Fairchild TJ, Doyle RP. Traveling the vitamin B12 pathway: Oral delivery of protein and peptide drugs. Angew Chem Int Ed Engl 2009; 48:1022-8.
47. Clardy SM, Allis DG, Fairchild TJ, et al. Vitamin B12 in drug delivery: Breaking through the barriers to a B12 bioconjugate pharmaceutical. Expert Opin Drug Deliv 2011;8:127-40.
48. Pappagallo M, Oaklander AL, Quatrano-Piacentini AL, et al. Heterogenous patterns of sensory dysfunction in postherpetic neuralgia suggest multiple pathophysiologic mechanisms. Anesthesiology 2000;92:691- 8.
49. Devor M, Govrin-Lippmann R, Angelides K. Na+ channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation. J Neurosci 1993;13:1976-92.
50. Oaklander AL. Mechanisms of pain and itch caused by herpes zoster (shingles). J Pain 2008;9:S10-18.
51. Garnock-Jones KP, Keating GM. Lidocaine 5% medicated plaster: A review of its use in postherpetic neuralgia. Drugs 2009;69:2149-65.
52. Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: A quantitative systematic review. PLoS Med 2005;2:e164.
53. Wolff RF, Bala MM, Westwood M, et al. 5% lidocainemedicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): A systematic review. Acta Neurol Scand 2011;123:295- 309.
54. Petersen KL, Rowbotham MC. Natural history of sensory function after herpes zoster. Pain 2010; 150:83-92.
55. Alvarez FK, de Siqueira SR, Okada M, et al. Evaluation of the sensation in patients with trigeminal postherpetic neuralgia. J Oral Pathol Med 2007;36:347- 50